VIDEO: ‘Encouraging’ safety data on Livdelzi in primary biliary cholangitis, cirrhosis
Click Here to Manage Email Alerts
PHILADELPHIA — In this video, Nancy S. Reau, MD, FAASLD, AGAF, highlights a presentation at the ACG Annual Scientific Meeting investigating the use of Livdelzi in patients with primary biliary cholangitis and cirrhosis.
Livdelzi (seladelpar, Gilead) received accelerated FDA approval in August and is approved for use in combination with ursodeoxycholic acid (UDCA) in adult patients who did not adequately respond to UDCA or as monotherapy for those who are intolerant to UDCA.
“If you do have a patient with cirrhosis and PBC, the data that was presented on seladelpar is very encouraging,” Reau, the Richard B. Capps Chair of Hepatology, associate director of solid organ transplantation and section chief of hepatology at Rush University, said. “[It] definitely emphasizes that this can be done safely.”
Reference:
- Crittenden DB, et al. Long-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis: Interim results for 2 years from the ASSURE study. Presented at: ACG Annual Scientific Meeting; Oct. 25-30, 2024; Philadelphia (hybrid meeting).
Collapse
Healio Interviews
Click Here to Manage Email Alerts